Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 235.81M P/E - EPS this Y 18.70% Ern Qtrly Grth -
Income -171.44M Forward P/E -1.58 EPS next Y 5.30% 50D Avg Chg -20.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -29.00%
Dividend N/A Price/Book 0.98 EPS next 5Y - 52W High Chg -63.00%
Recommedations 2.10 Quick Ratio 4.24 Shares Outstanding 52.67M 52W Low Chg 36.00%
Insider Own 1.92% ROA -49.01% Shares Float 24.10M Beta 1.02
Inst Own 109.19% ROE -92.17% Shares Shorted/Prior 9.99M/9.28M Price 5.77
Gross Margin - Profit Margin - Avg. Volume 218,906 Target Price 9.33
Oper. Margin - Earnings Date Nov 11 Volume 81,047 Change -3.19%
About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

ALX Oncology Holdings Inc. News
12/19/24 Top Midday Decliners
12/19/24 Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold'
12/18/24 ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
12/12/24 ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
12/10/24 ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
03:09 PM 3 US Penny Stocks With Market Caps Over $30M To Consider
08:00 AM ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/21/24 ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11/14/24 ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
11/07/24 ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/04/24 ALX Oncology Announces November Investor Conference Participation
11/01/24 ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
10/10/24 Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc
09/09/24 ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
09/04/24 ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
08/08/24 ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
08/06/24 ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
08/01/24 Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
08/01/24 ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial
07/31/24 ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
ALXO Chatroom

User Image OvernightSwingKing Posted - 5 hours ago

$ALXO $BDRX $AUTL In January 2025, ALX Oncology will share results from a key cancer trial at the ASCO Gastrointestinal Cancers Symposium (Jan 23–25). The trial tests their drug, evorpacept, combined with other cancer meds (Herceptin, Cyramza, and paclitaxel) on people with advanced stomach and GEJ cancer. They’ll share how safe it is, how well it works, and whether it helps patients live longer or slow the cancer. This info is a big step toward getting the drug approved for wider use. I’ve loaded heavy here, imo we will have a big month of Jan. Too many upcoming catalyst for this too stay this low!

User Image Xmanbull Posted - 6 hours ago

$ALXO $10 is my target

User Image OvernightSwingKing Posted - 8 hours ago

$ALXO This will run hard soon!! Setting up Imo…

User Image Golibajje Posted - 1 day ago

$ALXO Merry Christmas folks! Hope we have a great time with this investment here in future!

User Image NVDAMillionaire Posted - 2 days ago

$ALXO ALX Oncology Holdings Inc. (NASDAQ:ALXO): A Clinical-Stage Immuno-Oncology Leader Advancing Innovative Therapies https://beyondspx.com/article/alx-oncology-holdings-inc-nasdaq-alxo-a-clinical-stage-immuno-oncology-leader-advancing-innovative-therapies

User Image OvernightSwingKing Posted - 3 days ago

$ALXO 30 mil float with shorts representing 20% of that, any good news in January and this will go parabolic imo!!

User Image Golibajje Posted - 3 days ago

$ALXO Positive results are not just good for company but also good for CD47 inhibitors targeting various types of cancer as a whole. If the results are positive in upcoming read outs, this could be a buyout at minimum 2 BILLIONS, which puts the stock price around $40 per share! Note that Gilead acquired that junk magrolimab for $4.9 BILLIONS, which did not work! $ALXO on the other hand, had promising early results!

User Image TackaTa Posted - 3 days ago

$ALXO Very undervalued stock, strong pipeline, working therapy, very reliable partners, the fact that eli lilly has agreed to try their drug is indicative. Strong cash position, there are people on the board who are not random. With the small number of shares outstanding and the good news coming I expect this to go between $15 and $25.

User Image Moneywheel Posted - 3 days ago

$ALXO if we play paytience on that one we are going to end up making good money. Holding strong.

User Image OvernightSwingKing Posted - 3 days ago

$ALXO need to see this over $2 before news!!

User Image OvernightSwingKing Posted - 3 days ago

$ALXO $AISP Swings looking good this morning! Both have near term catalyst and should be strong swings heading into the new year!!

User Image OvernightSwingKing Posted - 4 days ago

$ALXO • Trial Results Coming: ALXO’s main drug, evorpacept, is being tested to treat cancers like stomach, bladder, and head and neck cancer. Big updates from these trials are expected in the first half of 2025, which could be game-changing if the results are good. • Approval Steps: If the trial results are strong, ALXO could move toward getting the drug approved in 2025. Might start adding some 👀

User Image TackaTa Posted - 5 days ago

$ALXO What are your expectations for Aspen-06?

User Image Moneywheel Posted - 6 days ago

$ALXO holding them. I like the set up. Wouldn’t be surprised if we see 3,47$ during the quarter of 2025.

User Image PrincessNemezis Posted - 6 days ago

$ALXO This company have great potential.

User Image FoolIggy Posted - 6 days ago

$ALXO imagine below $1/share as insiders & tutes keep dumping SP falls AND >20% shorts should keep retail away until this lands on new low that could see 1/2 of last years LOW at volume rates being dumped.

User Image TackaTa Posted - 6 days ago

$ALXO

User Image TackaTa Posted - 1 week ago

$ALXO Soon this stock will be in the spotlight and people like Michael will cry.

User Image Golibajje Posted - 1 week ago

$ALXO Jefferies gang took a short position yday.. that explains 700k short volume yday late afternoon just with in a matter of few mins! I see this Michael clown giving false ratings on biotech stocks more often without any logic! The logic explained here also baseless when I read it! Unfortunately, market goes with the false ratings and analysis! Let’s keep our fingers crossed for trading action today!

User Image TackaTa Posted - 1 week ago

$ALXO Why are you adding a rating to the company of someone who has a lower return than even the "slowest" investors?

User Image anachartanalyst Posted - 1 week ago

$ALXO https://anachart.com/wp-content/uploads/ana_temp/1734613297_soc-img.jpg

User Image TackaTa Posted - 1 week ago

$ALXO

User Image ElonMustLoveYou Posted - 1 week ago

$ALXO Jefferies downgraded ALX Oncology stock from 'Buy' to 'Hold' and significantly lowered the price target from $12.00 to $2.00

User Image terry9 Posted - 1 week ago

$NUKK over to $ALXO

User Image terry9 Posted - 1 week ago

$QMCO -> $ALXO

User Image Golibajje Posted - 1 week ago

$ALXO Alan Sandler was CMO of Mirati, which got acquired for $5.8 BILLIONS!! Know why is here with $100m company!!! Watch out for buyout in billions here! https://www.reuters.com/markets/deals/bristol-myers-squibb-acquire-mirati-48-billion-deal-2023-10-08/

User Image theBigDollarski Posted - 1 week ago

$ALXO I can't believe its going up....likely to break out.....kept going down....I kept buying......I'm up to my neck in the water....Sharks in the water......

User Image Thehunternotthevictim Posted - 1 week ago

$ALXO I see 3.50 no problem

User Image TackaTa Posted - 1 week ago

$ALXO

User Image ChartLaboratory_com Posted - 1 week ago

📈 $ALXO (ALX Oncology Holdings Inc.) Current Price: $1.79 (+16.23%) 📊 Measured Move: $1.20 → $1.88 → $2.56 💥 Day Trade Strategy: Entry above $1.75, Target: $2.00 📉 Swing Trade Strategy: Entry above $1.90, Target: $2.20–$2.56 📊 Chart: Link 💥 Join for More Insights: www.patreon.com/chartlab 🎄 Christmas Sale #Breakout #Momentum #SmallCapStocks 📈 $RZLV (Rezolve AI Limited) Current Price: $3.29 (+54.46%) 📊 Measured Move: $1.50 → $4.00 → $6.50 💥 Day Trade Strategy: Entry above $4.10, Target: $5.00–$6.50 📉 Swing Trade Strategy: Entry above $4.10, Target: $5.00–$6.50 📊 Chart: Link 💥 Join for More Insights: www.patreon.com/chartlab 🎄 Christmas Sale #TechStocks #AI #Growth

Analyst Ratings
UBS Buy Aug 16, 24
HC Wainwright & Co. Buy Aug 13, 24
Cantor Fitzgerald Overweight Aug 12, 24
Stifel Hold Aug 9, 24
Stifel Hold Aug 1, 24
HC Wainwright & Co. Buy Aug 1, 24
HC Wainwright & Co. Buy Jun 10, 24
Cantor Fitzgerald Overweight May 29, 24
Cantor Fitzgerald Overweight Apr 12, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Pinto Shelly VP, Finance and CAO VP, Finance and CAO Dec 29 Sell 11.0699 482 5,336 62,097 01/03/23
Randolph Sophia Chief Medical Office.. Chief Medical Officer Dec 29 Sell 11.0704 1,617 17,901 270,253 01/03/23
GARCIA PETER S Chief Financial Offi.. Chief Financial Officer Dec 29 Sell 11.0701 893 9,886 53,723 01/03/23
Pons Jaume President & CEO President & CEO Dec 29 Sell 11.0701 3,232 35,779 539,746 01/03/23
Randolph Sophia Chief Medical Office.. Chief Medical Officer Dec 16 Option 3.6 46,474 167,306 271,870 12/20/22
GARCIA PETER S Chief Financial Offi.. Chief Financial Officer Feb 07 Option 4.45 15,000 66,750 24,483 02/08/22
Pons Jaume President & CEO President & CEO Feb 03 Option 1.45 24,154 35,023 468,978 02/07/22
Randolph Sophia Chief Medical Office.. Chief Medical Officer Dec 15 Option 1.45 23,852 34,585 188,396 12/16/21
Lettmann Jason Director Director Dec 13 Sell 27.91 325,377 9,081,272 285,956 12/15/21
LSV Associates, LLC 10% Owner 10% Owner Dec 13 Sell 27.91 48,390 1,350,565 285,956 12/15/21
Lettmann Jason Director Director Dec 08 Sell 32.17 145,637 4,685,142 291,758 12/10/21
LSV Associates, LLC 10% Owner 10% Owner Dec 08 Sell 32.17 145,637 4,685,142 291,758 12/10/21
Pons Jaume President & CEO President & CEO Oct 19 Sell 54.64 16,700 912,488 444,598 10/20/21
GARCIA PETER S Chief Financial Offi.. Chief Financial Officer Sep 17 Sell 79.63 12,771 1,016,955 9,331 09/17/21
GARCIA PETER S Chief Financial Offi.. Chief Financial Officer Sep 17 Option 4.08 12,771 52,106 20,676 09/17/21
Randolph Sophia Chief Medical Office.. Chief Medical Officer Sep 13 Sell 77.48 7,387 572,345 156,815 09/13/21
Pons Jaume President & CEO President & CEO Aug 20 Sell 63.06 16,700 1,053,102 477,998 08/20/21